Navigation Links
Ardea Biosciences to Present at Two Upcoming Investor Conferences
Date:11/12/2010

SAN DIEGO, Nov. 12, 2010 /PRNewswire-FirstCall/ -- Ardea Biosciences, Inc. (Nasdaq: RDEA) announced today that Barry D. Quart, PharmD, president and chief executive officer, will present at the following upcoming investor conferences:

  • Lazard Capital Markets 7th Annual Healthcare Conference in New York, NY. Presentation: 1:40 p.m. EST on Tuesday, November 16, 2010; and
  • Piper Jaffray 22nd Annual Health Care Conference in New York, NY. Presentation: 1:00 p.m. EST on Tuesday, November 30, 2010.

These presentations will be webcast and can be accessed on the Investor Relations section of Ardea's website at www.ardeabio.com. Please connect to Ardea's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.

About Ardea Biosciences, Inc.

Ardea Biosciences, Inc., of San Diego, California, is a biotechnology company focused on the development of small-molecule therapeutics for the treatment of serious diseases.  RDEA594, our lead product candidate for the chronic management of hyperuricemia and gout, is a once-daily, oral inhibitor of the URAT1 transporter inhibitor in Phase 2 clinical development.  Our next-generation URAT1 inhibitor program is currently in preclinical development.  BAY 86-9766, formerly known as RDEA119, is a potent and specific inhibitor of mitogen-activated ERK kinase (MEK) for the treatment of cancer being developed under a global license agreement with Bayer HealthCare AG.  BAY 86-9766 has been evaluated in advanced cancer patients with different tumor types as a single agent in a Phase 1 study and is currently being evaluated in combination with sorafenib (Nexavar®; Bayer HealthCare, Onyx Pharmaceuticals) in a Phase 1/2 study.  Our two product candidates for the treatment of HIV, RDEA806 and RDEA427, are non-nucleoside reverse transcriptase inhibitors (NNRTIs), which have successfully completed a Phase 2a study in HIV patients and a human micro-dose pharmacokinetic study in healthy volunteers, respectively.

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995.  Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements.  Such statements include, but are not limited to, statements regarding our plans and goals, the expected properties and benefits of RDEA594, BAY 86-9766 (RDEA119), RDEA806, RDEA427 and our other compounds and the timing and results of our preclinical, clinical and other studies.  Risks that contribute to the uncertain nature of the forward-looking statements include risks related to the outcome of preclinical and clinical studies, risks related to regulatory approvals, delays in commencement of preclinical and clinical studies, costs associated with our drug discovery and development programs, and risks related to the outcome of our business development activities, including collaboration or license agreements.  These and other risks and uncertainties are described more fully in our most recently filed SEC documents, including our Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q, under the headings "Risk Factors."  All forward-looking statements contained in this press release speak only as of the date on which they were made.  We undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

(Logo:  http://photos.prnewswire.com/prnh/20091104/ARDEALOGO)

(Logo:  http://www.newscom.com/cgi-bin/prnh/20091104/ARDEALOGO)


'/>"/>
SOURCE Ardea Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Ardea Biosciences to Present Data on Lead MEK inhibitor, RDEA119, at EORTC-NCI-AACR Symposium
2. Ardea Biosciences to Present Data on Gout and Inflammation Programs at the 2008 ACR/ARHP Annual Scientific Meeting
3. Ardea Biosciences to Present at the UBS Global Life Sciences Conference and the Third Annual JMP Securities Healthcare Focus Conference
4. Cardea Technology Inc and Optasia Medical Ltd Announce Plans to Collaborate to Optimize Their Vertebral Fracture Assessment Tools
5. Ardea Biosciences to Present at the Piper Jaffray 21st Annual Health Care Conference
6. Ardea Biosciences Announces Appointment of Felix J. Baker, Ph.D. to Board of Directors
7. Ardea Biosciences to Present at the Oppenheimer 21st Annual Healthcare Conference
8. Ardea Biosciences Awarded a $733,438 Grant from the U.S. Government Under the Patient Protection and Affordable Care Act
9. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2008
10. Carna Biosciences Signs Reagent Supply Agreement with Caliper Life Sciences
11. Pressure BioSciences, Inc. to Discuss Second Quarter 2008 Financial Results and Provide Business Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... ... 2016 , ... Franz Inc. , an early innovator ... announced the availability of AllegroGraph 6, the leading Semantic Graph Database with certification ... Program (CCPT). AllegroGraph is the first Semantic Graph Database to be certified ...
(Date:2/8/2016)... England , February 8, 2016 ... Ltd ("Atlas Genetics" or the "Company"), the ultra-rapid Point-Of-Care (POC) ... to CE Mark its Chlamydia trachomatis (CT) test to be ... of the IVD Directive (98/79/EC), the CT test is now ... --> --> The launch of the io® ...
(Date:2/5/2016)... Feb. 5, 2016  In the pharmaceutical industry the ... host of launch activities including the identification and engagement ... activity is especially high in the oncology therapeutic area ... Practices and the Role of Medical Affairs in Oncology ... on oncology therapies find better ways to utilize medical ...
(Date:2/4/2016)... ... February 04, 2016 , ... Morf ... today announced an interactive FDA compliance training course, Writing Effective ... Professional Society) accredited interactive course on Morf Playbook—now conveniently available on smartphones and ...
Breaking Biology Technology:
(Date:2/4/2016)... -- The field of Human Microbiome research and ... hubs of the biotechnology industry. While the Human ... human microbiota, have garnered a lot of attention ... has literally exploded in terms of both basic ... on biomedical aspects of research, development, and commercial ...
(Date:2/3/2016)... 3, 2016 ... the "Emotion Detection and Recognition Market ... Others), Software Tools (Facial Expression, Voice Recognition ... Regions - Global forecast to 2020" ... http://www.researchandmarkets.com/research/d8zjcd/emotion_detection ) has announced the addition ...
(Date:2/2/2016)... 2016 Technology Enhancements Accelerate Growth of X-ray Imaging ... digital and computed radiography markets in Thailand ... Indonesia (TIM). It provides an in-depth ... well as regional market drivers and restraints. The study ... and market attractiveness, both for digital and computed radiography. ...
Breaking Biology News(10 mins):